134557-84-9

Upstream product

• 66605-57-0 (S)-N-tert-butoxycarbonyl-2-amino-3-phenylpropanol 
• 75-09-2 dichloromethane 
• 623-51-8 ethyl 2-sulfanylacetate 
• 141403-49-8 (2S)-2-[N-(tert-butoxycarbonyl)amino]-3-phenyl-O-(4-methylphenylsulfonyl)propan-1-ol 

Downstream Products

• 134557-87-2 ethyl (S)-<<2-<<(1,1-dimethylethoxy)carbonyl>amino>-3-phenylpropyl>sulfonyl>acetate 
• 134557-82-7 ethyl (S)-<<2-<<(1,1-dimethylethoxy)carbonyl>amino>-3-phenylpropyl>sulfinyl>acetate 

Relevant academic research and scientific papers

N-substituted cycloalkyl and polycycloalkyl α-substituted Trp-Phe- and phenethylamine derivatives

Novel unnatural dipeptoids of α-substituted Trp-Phe derivatives useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, colorectal tumors, or as antipsychotics are disclosed. Further the compounds are antianxiety agents, antiulcer agents, antidepressant agents, and are agents useful for preventing the withdrawal response produced by chronic treatment or use followed by chronic treatment followed by withdrawal from nicotine, diazepam, alcohol, cocaine, caffeine, or opiods. Also disclosed are pharmaceutical compositions and methods of treatment using the dipeptoids as well as processes for preparing them and novel intermediates useful in their preparation. An additional feature of the invention is the use of the subject compounds to prepare pharmaceutical and diagnostic compositions.

N-SUBSTITUTED CYCLOALKYL AND POLYCYCLOALKYL ALPHA-SUBSTITUTED TRP-PHE- AND PHENETHYLAMINE DERIVATIVES

Novel unnatural dipeptoids of α-substituted Trp-Phe derivatives useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, or as antipsychotics are disclosed. Further the compounds are antianxiety agents, antiulcer agents, antidepressant agents, and are agents useful for preventing the withdrawal response produced by chronic treatment or use followed by chronic treatment followed by withdrawal from nicotine, diazepam, alcohol, cocaine, caffeine, or opiods. Also disclosed are pharmaceutical compositions and methods of treatment using the dipeptoids as well as processes for preparing them and novel intermediates useful in their preparation. An additional feature of the invention is the use of the subject compounds to prepare pharmaceutical and diagnostic compositions.

Rationally designed 'dipeptoid' analogues of cholecystokinin (CCK): C-terminal structure-activity relationships of α-methyl tryptophan derivatives

This paper outlines the synthesis and C-terminal structure-activity relationships (SAR) of a series of α-methyl tryptophanylphenethylamide analogues of the neuropeptide cholecystokinin (CCK).CCK-B and CCK-A receptor binding affinities of these analogues are described and the contributions of the various side chains on the phenethylamide moiety to binding affinity are discussed.Several of the compounds prepared have CCK-B receptor binding affinities similar to that found with the endogenous neuropeptide CCK-26-33 (sulphated) (CCK-B, IC50 = 0.3 nM) and are highly selective over the CCK-A receptor.Amongst the most potent of the compounds synthesized are *,S*)>-β-3,7>dec-2-yloxy)carbonyl>amino>propyl>amino>benzenebutanoic acid 22, *,S*)>-3,7>dec-2-yloxy)carbonyl>amino>propyl>amino>-3-phenylpropyl>thio>acetic acid 28a and *,S*)>-3,7>dec-2-yloxy)carbonyl>amino>propyl>amino>-3-phenylpropyl>sulfonyl>acetic acid 32 which have CCK-B receptor binding affinities of IC50 = 0.3, 0.3 and 0.2 nM with CCK-A/B ratios of 220, 700 and 1000, respectively.CCK-B receptor selective ligands, 22, 28a and 32 were also shown to be potent anatagonists in blocking pentagastrin-evoked excitation in neurons of the rat hypothalamic ventro-medial nucleus (VMN) with the Ke values of 2.8, 23 and 5.9 nM, respectively. Keywords: cholecystokinin / dipeptoid analogues / structure-affinity relationships / α-methyl-tryptophan derivatives / C-terminal